20:19 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

Cellestia to start Phase I/IIa of CB-103 for Notch-dependent cancers

Cellestia Biotech AG (Basel, Switzerland) said it received Spanish regulatory approval to start an open-label Phase I/IIa trial of CB-103 to treat adults with Notch (NOTCH)-dependent advanced or metastatic solid tumors and hematological malignancies. The...
22:57 , Apr 7, 2017 |  BioCentury  |  Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch inhibitors. The...